December 16, 2020 10:16 AM EST
Financing

BioAt­la heads for Nas­daq on Wednes­day fol­low­ing $189M IPO, go­ing pub­lic with its pH-de­tect­ing can­cer treat­ments

Max Gelman

Senior Editor

Yet an­oth­er biotech is mak­ing its pub­lic de­but Wednes­day, and this one comes just a few months af­ter a $72.5 mil­lion Se­ries D

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

MIT sci­en­tists’ AI mod­el one-ups Al­phaFold 3, takes on ‘fun­da­men­tal is­sue’ in drug R&D

Is there still hope for Sum­mit's can­cer drug buried in the da­ta?

Bio­phar­ma lead­ers carv­ing a path for the in­dus­try’s LGBTQ+ com­mu­ni­ty

EMA con­sid­ers se­ri­ous eye con­di­tion a ‘very rare’ side ef­fect of semaglu­tide 

Up­dat­ed: Oma­da Health rose 21% in its pub­lic mar­ket de­but

sponsored

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py ...

A service from the Financial Times